Journal profile · Medicine-Endocrinology, Diabetes and Metabolism
Frontiers in Clinical Diabetes and Healthcare
ISSN 2673-6616 · Frontiers Media S.A. · Switzerland
Frontiers in Clinical Diabetes and Healthcare: CAS Zone 4 · Medicine (2026 Xinrui edition); impact factor 3.5 (journal website); fully open access; APC charged, amount not published; median 70 days to acceptance (104 articles, last 24 months); 91 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Frontiers in Clinical Diabetes and Healthcare is published by Frontiers Media S.A. and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are Diabetes Management and Research, Diabetes Management and Education and Diabetes, Cardiovascular Risks, and Lipoproteins, together about 40.6% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)
Frontiers in Clinical Diabetes and Healthcare is a multidisciplinary journal that contributes to the understanding of diabetes and its treatment in clinical settings. Led by Field Chief Editor Dr. Manfredi Rizzo (University of Palermo, Italy), Frontiers in Clinical Diabetes and Healthcare welcomes submissions in all areas of clinical diabetes research which improve treatment experiences and quality of practices for patients. Manfredi Rizzo has been elected as a member of the Board of Directors of the International Atherosclerosis Society (IAS) for the years 2025-2027 and as President of the Central European Diabetes Association (CEDA) for the years 2026-2030. Frontiers in Clinical Diabetes is currently indexed in PubMed Central (PMC), the DOAJ, Scopus, and Web of Science Emerging Sources Citation Index (ESCI). Focusing on the clinical aspects of diabetes, the journal covers the following subject areas: diabetes cardiovascular complications diabetes clinical epidemiology diabetes health services and health economics diabetes inequalities diabetes innovative devices diabetes, lifestyle, and metabolic syndrome diabetes multiorgan complications diabetes nephropathy diabetes nutrition and dietetics diabetes and pregnancy diabetes self-management diabetes therapies. With a focus on the clinical aspects of diabetes, ultimately aiming to improve treatment experiences and quality of treatment for patients, the journal is particularly interested in submissions that explore therapies, nutrition and dietetics, and self-management from a patient perspective. Furthermore, the journal welcomes submissions which support and advance the UN’s Sustainable Development Goals (SDGs), notably SDG 3: good health and well-being for all at all ages. Manuscripts that focus solely on general medical care, disease treatment, or the use of medical equipment without a relevance to clinical diabetes and healthcare are not suitable for publication in this journal. The journal's scope does not include studies that do not contribute to the understanding, prevention, and management of diabetes and its complications. Frontiers’ journals require that manuscripts primarily comprising computational studies of public data, must include appropriate validation. Please refer to the Frontiers Standards for research methodology policy, for more information. Manuscripts not adhering to these standards will not be considered. Frontiers in Clinical Diabetes and Healthcare is committed to advancing develo
From the journal's Aims & Scope
Research area (LetPub): Medicine-Endocrinology, Diabetes and Metabolism
Editorial board by country: none in mainland China; most named Spain 4, Italy 3, Taiwan, China 2, United States 1, United Kingdom 1 (17 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diabetes Management and ResearchMedicine16.2%
- Diabetes Management and EducationMedicine14.2%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine10.2%
- Diabetes Treatment and ManagementMedicine8%
- Diabetes and associated disordersBiochemistry, Genetics and Molecular Biology6.7%
- Mobile Health and mHealth ApplicationsHealth Professions5.4%
- Pancreatic function and diabetesMedicine4.3%
- Gestational Diabetes Research and ManagementMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Endocrinology & Metabolism | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPublisher website
Other: EBSCO, ProQuest, Dimensions, CNKI, CLOCKSS, Crossref
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.5Publisher website ·
- CiteScore 2026-06
- 3.5LetPub ·
- CiteScore (publisher)
- 3.5Publisher website ·
- SJR 2026-06
- 0.84LetPub ·
- SNIP 2026-06
- 0.94LetPub ·
- h-index
- 20OpenAlex ·
- i10-index
- 79OpenAlex ·
- 2-year mean citedness
- 2.54OpenAlex ·
- Self-citation rate
- 2.9%LetPub ·
- Share of gold OA articles
- 99.44%LetPub ·
Volume
- Articles per year
- 76LetPub ·
Articles by year OpenAlex count · 430 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 121 | 121 | 50 |
| 2025 | 91 | 91 | 268 |
| 2024 | 49 | 49 | 346 |
| 2023 | 66 | 66 | 623 |
| 2022 | 77 | 77 | 886 |
| 2021 | 25 | 25 | 231 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
70 daysMedian, submission to acceptance · P25–P75 47 days – 119 days
- Acceptance to online
- median 21 days (104 articles)
- Submission to online
- median 101 days
- Sample
- 104 articles with submission and acceptance dates (230 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 13 weeksLetPub ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | CHF 1,950 | Yes | CC BY | |
| OpenAlex | CHF 1,950 | — | — | |
| LetPub | USD 2,125 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Keywords
- 5–8
Policy excerpts from the journal's websiteAI use, Conflicts of interest, License & copyright, Open access, Peer review
- AI use Use of AI to create written or visual content
Authors should not list a generative AI technology as a co-author or author of any submitted manuscript. Generative AI technologies cannot be held accountable for all aspects of a manuscript and consequently do not meet the criteria required for authorship. If the author of a submitted manuscript has used written or visual content produced by or edited using a generative AI technology, this use mu…
Source ↗Publisher website ·- Conflicts of interest Safeguards against financial conflicts of interest
Only leading researchers acting as Associate Editors, who are not part of Frontiers' staff, can make acceptance decisions based on reviews performed by external experts acting as Community Reviewers or Reviewers. None have a financial incentive to accept articles, i.e. they are not paid for their role as Associate Editor or community Reviewer, and any award scheme is not linked to acceptances of m…
Source ↗Publisher website ·- License & copyright Open access and copyright
Figures/tables/images published under CC-BY; permission needed for third-party copyrighted material. Model summary
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Open access Open access and copyright
Open access under CC-BY 4.0 license; author retains copyright. Model summary
All Frontiers' articles from July 2012 onwards are published with open access under the Creative Commons CC-BY license (the current version is CC-BY, version 4.0). This means that the author(s) retains copyright, but the content is free to download, distribute, and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article. Upon submission, the author(s)…
Source ↗Publisher website ·- Peer review Peer review
CrossMark policy to maintain content and alert readers to changes. Model summary
Our rigorous, transparent peer review process combines expert review and constructive dialogue to strengthen your manuscript.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Frontiers Media S.A.
- Country or region
- Switzerland
- Language
- English
- ISSN
- 2673-6616
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Frontiers in Clinical Diabetes and Healthcare
What CAS zone is Frontiers in Clinical Diabetes and Healthcare in?
In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Frontiers in Clinical Diabetes and Healthcare?
The journal's website gives an impact factor of 3.5; this is the journal's own figure, as LetPub lists none for it; CiteScore 3.5, h-index 20.
How long does peer review take at Frontiers in Clinical Diabetes and Healthcare?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 70 days (interquartile range 47–119 days); authors report an average review time of about 13 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Frontiers in Clinical Diabetes and Healthcare based?
Of the 17 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Spain (4), Italy (3) and Taiwan, China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Frontiers in Clinical Diabetes and Healthcare?
According to LetPub and DOAJ records, Frontiers in Clinical Diabetes and Healthcare is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and PMC; that list has not been checked against each database.
Is Frontiers in Clinical Diabetes and Healthcare open access, and what is the APC?
Frontiers in Clinical Diabetes and Healthcare is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .